Trial Profile
Phase 2B Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Tuvatexib (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Sponsors VidacPharma
- 26 May 2018 Status changed from not yet recruiting to recruiting.
- 15 May 2018 Status changed from planning to not yet recruiting.
- 16 Oct 2017 New trial record